Gilead: The $10.5 Billion Loss Is Bookkeeping — the Stock Has Already Priced in the Fix

Gilead Sciences reported a $10.5 billion net loss in the second quarter of 2026 — a loss of $8.45 per share. Read on its own, that sounds like a company in crisis. It is not. The stock barely moved on the number and is still trading near its high for the year, around $146 a share. Understanding why the loss fooled almost no one is the key to reading this stock, because the number is a distraction — and the real story is what Gilead spent roughly $16 billion to build during the same stretch of time.

The loss is bookkeeping, not the business

The loss did not come from selling fewer drugs or mismanaging the company. It came from accounting rules that trigger when a business buys another one for its pipeline. In the first half of 2026, Gilead closed three acquisitions. When you buy a biotech, the value of its unlaunched drug candidates is recorded as an asset; the moment the deal closes, accounting rules force you to write that value off immediately, as a one-time expense called "acquired in-process research and development" (IPR&D). No cash actually left the company for it.

In the second quarter that one-time charge was $11.2 billion — about $9 a share. Strip it out and the picture flips. Gilead would have earned roughly $2.27 a share for the quarter, up about 13% from a year ago, and the underlying business was genuinely re-accelerating. Total revenue rose 10% to $7.8 billion, the company's strongest second-quarter growth in three years and above what analysts expected. The HIV franchise grew 12% to $5.7 billion, its cancer drug Trodelvy grew 26% to $457 million, and its liver drug Livdelzi more than doubled to $167 million. Underlying operating margin was about 49 cents on every dollar of product sales. On top of all that, management raised its full-year sales forecast.

So the two facts that look like opposites — a scary loss and a business accelerating — are the same quarter. The loss is the price of buying the future.

Six weeks, $16 billion, and the end of the one-franchise era

Why buy at all? Because Gilead has carried a problem for thirty years, and the loss is the cost of trying to fix it. HIV is the engine. In 2025, HIV drugs were roughly 72% of the company's $28.9 billion in product sales. For decades that was a crown jewel; the market's long-standing worry is what happens when it plateaus, faces price pressure, or loses ground. Gilead's earlier attempts to branch out — a foray into heart disease among them — have mostly underdelivered.

On September 9, at the Wells Fargo Healthcare Conference, the company's chief medical officer, Dietmar Berger, laid out the answer: a three-pillar strategy built on virology (the HIV anchor), oncology, and inflammation. And to fund it, Gilead spent roughly $16 billion — including contingent milestone payments — in about six weeks. It bought Arcellx for about $7.8 billion (its anito-cel cell therapy for multiple myeloma), Tubulis for up to $5 billion (antibody-drug-conjugate cancer drugs), and Ouro Medicines for about $2 billion (T-cell therapies for autoimmune disease). Management said the pipeline is now "broad enough to require more selective prioritization" — its own admission that it has had to start saying no.

The most concrete near-term proof is anito-cel. It is due for an FDA decision on December 23, with a launch targeted for the end of 2026. Gilead says that in more than 400 treated patients it has seen no delayed neurotoxicity or Parkinsonism — side effects that show up at rates up to 10% in competitors' therapies — an important distinction in a crowded cell-therapy market.

What the spending left behind — and what the multiple says

The trade-off is cash. Gilead began the year with $10.6 billion and had $3.2 billion left by the end of June, after about $11.3 billion in cash outflows to pay for the deals. The dividend is still safe: it raised its payout 3.8% earlier this year, its 11th consecutive annual increase, and at $0.82 a quarter it is easily covered by the roughly $3.6 billion of operating cash flow Gilead generated in the second quarter alone. But the cushion is thinner, and most of what it bought is not yet earning revenue.

That matters for the price. The stock at about $146 sits near its 52-week high of $157 and well above its low near $108. This is not a value stock; the market has already paid up for the diversification story. On the full-year earnings Gilead expects once the one-time charges are removed — roughly $8.50 to $8.85 a share — a $146 price is about 17 times forward earnings. That is a normal, not cheap and not rich, multiple for a company this size, and it sits a little above where Gilead's multiple has typically traded.

So the honest read splits cleanly. The "loss" scare is overdone, and that part is settled. The business really did re-accelerate, and it has genuinely moved to cut its dependence on HIV. But the stock is no longer on sale, and a higher multiple is only fair if the new engines actually land. The bear case is real: HIV is still most of the sales and its flagship drug Biktarvy is growing just 7%, Gilead's existing cell-therapy line is shrinking (down 14% in the quarter), and $16 billion of the story is still just pipeline.

The next two to four quarters decide it. The question is whether anito-cel clears the December 23 FDA decision and launches on schedule, whether cell-therapy sales stop falling, and whether the prevention franchise — which just passed a $1 billion quarter, a $4 billion annual run rate — keeps compounding. If the oncology bets convert into real sales and HIV holds, the higher multiple is earned. If they stay pipeline and HIV only drifts, Gilead is a fine business at a fair price — not a bargain. Either way, the scary loss number is not the thing to base a decision on.